Background Dickkopf-1 (DKK1) is a secreted modulator of Wnt signaling that is frequently overexpressed in tumors and associated with a poor prognosis. In this study, we demonstrate an approach for clinically validating a RNAscope chromogenic in-situ hybridization...
![A Novel Image Analysis Assay for Determining Programmed Death-Ligand (PD-L1 [22C3]) in Non-small Cell Lung Cancer that Accounts for Tissue and Alveolar Macrophages (Poster No. 435 #AACR2021)](https://flagshipbio.com/wp-content/uploads/2021.AACR_ClinDxPoster435_Final_29MAR2021_low-1024x576-1.jpg)
Background The Dako PD-L1 (22C3) antibody is used to measure tumor PD-L1 levels in non-small cell lung cancer (NSCLC), serving as a companion diagnostic to the check point inhibitor drug pembrolizumab. However, interpretation of the PD-L1 (22C3) immunohistochemistry...
Key takeaways An image analysis-based algorithm was used to assess CD8 expression in numerous tumor nests in non-small cell lung cancer, bladder, and melanoma tumor samples Measuring CD8 expression within tumor nests rather than averaging across a whole tissue section...
Summary View a scientific, collaborative success with our client, Heat Biologics, presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 medical oncology conference. We cover image analysis of tumor infiltrating lymphocytes (TIL) and more.
ABSTRACT PD-L1 positivity in tumor-associated macrophages has been related to a favorable response to anti-PD-1 and PD-L1 targeted therapies. This concept has driven interest in specifically identifying macrophages in PD-L1 stained tissues, but pathologists often have...
BACKGROUND F-06647020, an ADC comprising a humanized monoclonal antibody against PTK7, a cleavable valine-citrulline linker, and an auristatin payload, is being investigated in an ongoing Phase I clinical trial in patients with advanced solid tumors. We hypothesized...
Sign up to receive industry and company news, including The Cut Point, Flagship’s quarterly e-newsletter.
NEWS
Accomplished industry executive strengthens company’s position as a leader in spatial biology and biomarker analytics.BROOMFIELD, CO - September 27, 2022 — Flagship Biosciences, Inc., a leader in spatial biology and biomarker analytics services, announced the hiring...
Acquisition significantly expands Flagship’s portfolio of biomarker and analytics servicesBroomfield, CO – August 31, 2022 — Flagship Biosciences, Inc., a leader in spatial biology and biomarker analytics services, announced the acquisition of Interpace Pharma...
The journal Scientific Reports recently published a manuscript on the validation of Flagship’s new digital assay, Tissue Insight (TI) 22C3 NSCLC.1 This technology facilitates the otherwise cumbersome process of quantifying programmed cell death ligand 1 (PD-L1)...
EVENTS
Visit us at booth 821 at the ASGCT Annual Meeting. We help you analyze more data in more depth, so you can produce more effective therapies. Attending the ASGCT Annual Meeting? Schedule a meeting with our team to discuss our: AI-powered digital pathology solutions...
Visit Us at Booth 2866 in the West Building, Level 2 Flagship Biosciences is your source for spatial biology expertise, moving your research forward every step of the way. Our mission is to explore complex biomarkers within the context of disease in order to advance...
Reuniting 100+ leading experts in biotech, pharma, and academia. February 21-23, 2023. We’re headed to Boston to join other leading experts in biotech, pharma and academia to discuss obstacles in clinical trials and strategies for delivering safer and more effective...